A prospective study using a combination of paclitaxel and bevacizumab in breast cancer discovered that VEGF-A expression was not correlated with treatment outcome, however the study revealed potential biological and prognostic roles of VEGF-VEGFR combinations 38. The gene discussed is KDR; the disease is breast cancer.